Joseph Kim, Inovio CEO (Andrew Harnik, AP Images)
December 3, 2020 07:07 AM ESTUpdated 01:10 PM
Coronavirus

Covid-19 roundup: In­ovio en­lists plas­mid man­u­fac­tur­er to re­place the one it's in le­gal feud with; Cy­ber­at­tacks spot­ted tar­get­ing vac­cine dis­tri­b­u­tion 

Max Gelman

Senior Editor

Nicole DeFeudis

Editor

Amber Tong

With its Phase II tri­al fi­nal­ly un­der­way, In­ovio has en­list­ed an­oth­er key man­u­fac­tur­ing part­ner to hit its goal of hun­dreds of mil­lions of dos­es of …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

BioN­Tech set­tles with NIH, UPenn in Covid vac­cine dis­putes and will pay roy­al­ties

FDA ap­proves sub­cu­ta­neous ver­sion of Bris­tol My­er­s' Op­di­vo

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

J&J part­ners on STAT6; As­traZeneca, Dai­ichi with­draw lung can­cer drug EMA app

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

A service from the Financial Times